CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT. CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.Services Agreement • August 9th, 2016 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
SciClone Pharmaceuticals International Ltd., Ugland House, South Church Street George Town, Grand Cayman, Cayman Islands, USA (“Customer”)
AMENDMENT NO. 4Manufacturing Services Agreement • August 9th, 2016 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 4 TO MANUFACTURING SERVICES AGREEMENT (this “Amendment No. 4”) is made as of May 31, 2016, by and between SciClone Pharmaceuticals International Ltd. (“Customer”); and Lonza Sales Ltd (“Lonza’’).
Manufacturing Services AgreementServices Agreement • August 9th, 2016 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
SciClone Pharmaceuticals International Ltd. Ugland House South Church Street George Town, Grand Cayman Cayman Islands
AMENDMENT NO. 3 TO MANUFACTURING SERVICES AGREEMENTManufacturing Services Agreement • August 9th, 2016 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 3 TO MANUFACTURING SERVICES AGREEMENT (this “Amendment No. 3”) is made as of December 9th, 2015, by and between SciClone Pharmaceuticals International Ltd. (“Customer”); and Lonza Sales Ltd (“Lonza”).
AMENDMENT NO. 1 TO MANUFACTURING SERVICES AGREEMENTManufacturing Services Agreement • August 9th, 2016 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO MANUFACTURING SERVICES AGREEMENT (this “Amendment No. 1”) is made as of March 22, 2015, by and between SciClone Pharmaceuticals International Ltd. (“Customer”); and Lonza Sales Ltd (“Lonza”).
